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Abstract: 
Hepatitis C virus (HCV) is the major cause of chronic liver disease such as acute and chronic hepatitis, liver 
cirrhosis and hepatocellular carcinoma. This virus is responsible for more than 60% of chronic hepatitis. Based on 
its genetic variability, HCV is classified into at least six genotypes and a series of subtypes (1a, 1b, 2a, 2b, 3a, 3b, 4, 
5a, and 6a), while Genotype one is difficult to treat but genotypes 2 and 3 are easy to treat. Different genotypes are 
seen in different parts of the world. HCV genotyping is important for prediction of success of chemotherapy and 
progression of liver diseases. So recent studies have focused on determination of HCV genotypes.  
In this study, viral genomic of 86 patients (from different laboratories of Esfahan) extracted from sera were detected 
by nested-real time (RT) PCR. PCR products were digested with proper enzymes and studied by restriction fragment 
length polymorphism (RFLP). The results of PCR-RFLP were as follows: 1a (52.3%), 1b (11.6%), 3a (29.1%), 2a 
(2.3%), 4 (4.7%). Our results showed that types 1a and 3a were the most prevalent HCV genotypes in our samples. 
The results of this study will guide clinicians in successful monitoring and treatment of HCV patients in our region. 
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INTRODUCTION: 
Hepatitis C virus (HCV) is a significant etiology of 
chronic hepatitis and the leading cause of hepatic 
transplantation in the world [1]. It is well established 
now that hepatitis C virus (HCV) is the leading cause 
of blood borne non-A, non-B hepatitis worldwide [2, 
3].  
 HCV infection is a global health problem and it is 
estimated that 200 million people of the world 
population are infected with HCV [4]. HCV is a 
major cause of chronic liver disease, hepatocellular 
carcinoma, and the single most common indication 
for liver transplantation [5]. An estimate of 53,000 
deaths per year caused due to HCV in world. Most 
HCV infected people remained unidentified until the 
development of late symptoms, while some remained 
carrier through their life and do not develop any 
complication [6]. 
This virus was discovered in 1989. It is an 
approximately 9.6 kb single stranded positive sense 
RNA virus. HCV belongs to the Flaviviridae family 
and Hepacivirus genus. The structure of the RNA is 
composed of three parts; structural (C- E1 – E2), 
nonstructural (NS1 –NS2 - NS3 –NS4 - NS5), and 
two untranslated regions (5´-UTR and 3´-UTR) at 
two ends of the viral genome [7, 8]. 5'-UTR is highly 
conserved and therefore preferred for diagnosis [9]. 
This region has some specific internal ribosomal 
entry sites (IRES) in its structure which help to 
distinguish between genotypes and subtypes [10, 11]. 
E1 and E2 regions display the most variable part of 
its genomic RNA [12]. The genetic variability is due 
to high mutation rate in the envelope gene coupled 
with the absence of a proofreading function in the 
virionencoded by RNA polymerase [13]. Based on 
genetic differences among HCV isolates, hepatitis C 
virus species is classified into 6 genotypes with 120 
subtypes [8, 14, 15]. Genotype frequencies vary by 
geographic region. Some genotypes (1a, 1b, 2a, 2b, 
3a) are widely distributed around the world [16], 
while others have a more restricted distribution. 
Genotype 4 is predominant in the Middle East 
(particularly Egypt), Zaire and Burundi [17] while 
genotype 5 has so far been mainly found in South 
Africa [18]. Genotypes 1 and 3 are commonly found 
in Iran [19, 20].  
Genotyping is useful tool for investigating outbreaks 
and for understanding the epidemiology of the 
infection. Clinically, genotyping of HCV is important 
for predicting treatment responses and for 
determining the duration of antiviral therapy. 
Response to interferon (IFN)-based therapies in 
patients infected with HCV genotype 1 and 4 is much 
lower than in genotypes 2 and 3 [20, 21]; Thus, HCV 
genotyping is recommended before starting 
treatment. 
HCV genotyping is performed by several molecular 
techniques, such as sequencing of cloned genome, 
hybridization, Restriction Fragment Length 
Polymorphism (RFLP) and genotype-specific primer 
PCR [9]. The gold standard method for HCV 
genotyping is sequencing but this technique is 
expensive and requires many equipments and 
facilities. Contrary, RFLP is a sensitive and cost-
effective method. In RFLP, part of 5'-UTR is 
amplified by PCR and the amplicon is digested by 
restriction enzymes. The genotype of the HCV is 
determined based on the pattern of the fragments 
following digestion [22]. 
In the current study, we aimed to determine 
distribution of HCV genotypes and their prevalence 
in Esfahan by PCR-RFLP.  
 
MATERIALS AND METHODS: 
Serum Samples during 2013-2014, eighty six blood 
samples were obtained from HCV patients who were 
found to be HCV positive from different laboratory 
in Esfahan. HCV infection in patients had been 
confirmed by positive results in HCV-Ab. All 
patients had elevated serum aminotransferases for at 
least 6 months, a positive test for anti-HCV 
antibodies (thirdgeneration ELISA [Ortho 
Diagnostics, Raritan, N. J.]), and HCV RNA in serum 
by reverse transcription nested PCR for the 5'-UTR 
of the HCV genome [23, 24]. Patients including 54 
males and 32 females, and the mean age was 39 
(ranges was varying from 19 to 60 year). The 
collected bloods from the patients were stored at -70 
°C until tested. 
 
HCV RNA extraction For detection of HCV RNA 
in serum and for genotyping studies, RNA was 
extracted from fifty μl of serum by acid guanidinium-
isothiocyanate- phenol- chloroform method [25], then 
precipitated with isopropanol, and rinsed with 70% 
cold ethanol. The RNA pellet was resuspended in 25 
μl of diethyl pyrocarbonate (DEPC) treated water. 
 
cDNA synthesis Five microliter of the extracted 
RNA was used as the template for synthesis of cDNA 
by QIAGEN Sensiscript RT kit. In a microtube, 2 μl 
10x RT buffer, 2 μl 5mM dNTPs, 2 μl 10mM random 
primer, 1 μl 10U/μl RNase inhibitor were added. The 
final volume of RT reaction was adjusted to 20 μl by 
DEPC water. The reaction tube was incubated at 37 
ºC for 1 hour and the product was kept at -20 ºC. 
 
PCR genotyping primers For specific and nested 
PCR, four oligonucleotide primers form 5'-UTR of 
HCV were designed using generunr (Hastings 
software) and synthesized at the Cinna Gene 
Company (Iran). In the first round of PCR, the 
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primers corresponded to HCV-1 sense oriented 
nucleotides -268 to -251 F1, numbered according to 
Bukh et al., [26] and antisense nucleotides -4 to -22 
R1. For the second round, the primer F2 
corresponded to sense-oriented nucleotides -199 to -
183 and R2 corresponded to antisense nucleotides -26 
to -43. The sequences of primers were follow: 
F1: 5'- AGCGTCTAGCCATGGCGT -3' 
R1: 5'- GCACGGTCTACGAGACCT-3' 
F2: 5'- GTGGTCTGCGGAACCGG -3' 
R2: 5'- GGGCACTCGCAAGCACCC -3' 
 
PCR The first round was carried out for 30 cycles 
which consisted of initial denaturation at 94°C for 5 
min, denaturation at 94°C for 35 s, annealing at 58°C 
for 40 s, extension at 72°C for 45 s and, the final 
extension at 72°C for 5 min. The second round was 
followed for 25 cycles which consisted of initial 
denaturation at 94°C for 5 min, denaturation at 94°C 
for 35 s, annealing at 64°C for 40 s, extension at 
72°C for 45 s, and the final extension at 72°C for 5 
min. The 174-bp second PCR product was submitted 
to electrophoresis by using a 1.5% agarose gel in 
0.5X TBE buffer, and was visualized by ethidium 
bromide staining under ultraviolet light [27].  
 
Genotyping by RFLP To do RLFP of HCV, 25 μl of 
each nested-PCR products were divided into three 
tubes containing appropriate buffers. Restriction 
enzymes, Apa I, Hinf I, EcoR II and Bsh1236 
(Fermentas, Co.) used as the following combinations: 
1. Apa I / Hinf I; 2. EcoR II/Hinf I; 3. Bsh1236 I. 
[28]. The tubes were incubated with 1 U of the 
enzyme mixture for 3 h at 37°C. The digested 
products were separated by electrophoresis on 
polyacrylamide 13% gel at 100 V for 3 h and then the 
DNA fragments were visualized by ethidium bromide 
staining.  
 
RESULTS: 
Primarily, serum samples were screened for anti-
HCV antibody. Sera samples from 86 patients were 
positive for anti-HCV antibody and all of them also 
were showed positive by nested-PCR. Figure 1 shows 
the 174 bp nested RT-PCR amplification of HCV 
RNA extracted from blood samples. Table one 
demonstrates cutting sites of Hinf I, Apa I, EcoR II 
and Bsh1236 I restriction enzymes for different 
strains of HCV as published by Bukh et al [26]. 
Figure 2 shows the pattern of the digested products of 
1a and 3a HCV genotype by RFLP on 
polyacrylamide gel electrophoresis.  
In this present study, 5 subtypes were detected. The 
RFLP results were as follows: 1a (52.3%), 1b 
(11.6%), 3a (29.1%), 2a (2.3%), 4 (4.7%). This 
indicates that a high percentage of HCV infected 
patients in Iran are infected with 1a or 3a genotypes 
(Table 2). Analysis of population previously infected 
with HCV showed that 9.3% of patients were less 
than 25 years of age; also 30.2% were above 50 years 
old and demonstrated that 3a was the most frequent 
genotype in this patients. 
 
 
Fig 1:  Ethidium bromide stained gel of PCR products amplified with HCV primers. DNA 100 bp markers 
(lane M), samples positive 
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A       B  
Fig 2. 12% polyacrylamide gel electrophoresis of RLFP patterns of genotypes of 1a and 3a. Marker; DNA 100 
bp (lane M), A: Genotype 1a (129, 97 and 97 bp) B: Genotype 3a (129, 145 and 99 bp) 
 
 
Table 1: Demonstrates cutting sites of Hinf I, Apa I, EcoR II and Bsh1236 I restriction enzymes for different 
strains of HCV as published by Bukh et al. [26] 
 
Genotype 
 
Segment (bp) 
         Tube A                         Tube B                      Tube C 
1a 97 97 129 
1b 97 97 99 
2a 97 174 174 
2b 174 174 174 
3a 129 145 99 
3b 97 145 99 
4 97 145 129 
5 97 174 99 
6 97 97 174 
 
Table 2:  Hepatitis C virus genotypes in 86 patients with RFLP method 
Genotype Number % 
1a 45 52.3 
1b 10 11.6 
2a 2 2.3 
3a 25 29.1 
4 4 4.7 
Total 86 100 
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DISCUSSION: 
HCV contain a positive polarity, single-stranded 
RNA genome with 5’ and 3’ UTR. The core (C), 
envelope 1 (El) and envelope 2 (E2) proteins are 
encoded at the 5’ terminus and the non-structural 
proteins (NS) are encoded at the 3’ terminus of the 
single open-reading kame of the genome [29].  
HCV infection is still one of the major health 
problems in the world. HCV nucleotide sequences, 
which are different from each other up to 30 % of the 
time, are divided into six genotypes and more than 80 
subtypes [4].  
Different genotypes of HCV demonstrate different 
geographical distribution, besides, the severity of 
HCV hepatitis and the outcome of chemotherapy 
against HCV genotypes is not similar. HCV type 1 
infections are common worldwide. Genotypes 1, 2 
and 3 are more common genotypes and are observed 
mostly at Europe, North America, China, Japan and 
Australia. There are more significant differences in 
the distribution of subtypes. Type 1a often was found 
in Northern Europe and North America, and Iran; 
type 1b is the most common genotype in Japan, 
South and Eastern Europe. Genotype 1 was found in 
71 % of the infected population in USA and type 2 is 
rarer than type 1 in the world. HCV subtypes 2a and 
2b are relatively common in North America, Europe 
and Japan and subtype 2c is most common in 
northern Italy [9, 30, 31]. 
The majority of patients are infected with HCV 
genotype 3 in Thailand, Malaysia, India and Pakistan 
[32]. HCV genotype 4 appears to be prevalent in 
North Africa and the Middle East. This genotype is 
reported to be dominant in Yemen, Kuwait, Saudi 
Arabia, Iraq, Zaire, Gabon and Gambia. Genotypes 5 
and 6 seem to be confined to South Africa and 
Southeast Asia, respectively [9, 33, 34]. In our study 
HCV genotypes were found, 1a (52.3%), 1b (11.6%), 
3a (29.1%), 2a (2.3%), 4 (4.7%).   
HCV genotyping has been particularly important for 
studying the relationship between type/subtype and 
clinical status, pathogenesis, and disease outcome. 
This is useful for vaccine research and development, 
specifically because different genotypes often 
respond differently to antiviral treatment [9, 35, 36]. 
In addition to treatment purposes, detection of HCV 
genotypes in different regions can be used for the 
purpose of molecular epidemiology [37]. 
HCV genotyping can be performed with several 
molecular techniques. According to Furione et al the 
sensitivity of RFLP for genotyping of HCV is 96.2 % 
[22]; therefore, we decided to use RLFP for 
genotyping of HCV in chronic hepatic patients.  
As a result of this study genotype 1a (52.3%) was the 
most common HCV genotype in our region. In 
studies conducted in our country also the 
predominant type is often 1a. The results of this study 
will guide clinicians in successful monitoring and 
treatment of HCV patients in our region. 
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